Devgen Pharma has first-in-class oral small molecule inhibitors of PKCε, PKCθ and ROCK
with excellent efficacy in standard models inflammatory diseases. These kinases are
closely related and modulate key disease pathways. Inhibition of these targets results in
decrease of a number of cytokines, which is a validated therapeutic mechanism for control
of inflammation.
The company’s innovative chemical strategies have resulted in molecules with a variety of
pharmaceutical properties, leading to opportunities to exploit the targets in multiple separate
conditions, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis
and chronic obstructive pulmonary disease (COPD), resulting in multiple partnering and
development opportunities.
The Company’s compounds have many potential advantages over older, less targeted small
molecules such as methotrexate. Biological and chemical target validation also suggests a
superior profile over other kinase targets such as p38. A small molecule approach has
clearly benefits over the more recently introduced biologicals:

• Small molecules have a broader, though still targeted set of effects that may
  increase the chance of providing relief of inflammation.
• Biologicals are expensive to produce and must be administered by injection.
  The Company’s small molecules will be comparatively inexpensive to produce
  and will be administered orally.

The Company also has some assets that fall outside its focus on inflammation, which may
offer the potential for early licensing revenues. One of these, a project targeting the Kv4.3
ion channel, is one of the Company’s most advanced programs. Its goal is to develop bestin-
class orally-available treatments for acute and chronic atrial fibrillation, the most
common heart rhythm abnormality and one that is becoming even more frequent as the
population ages.